

Marked Improvement of Treatment-resistant Tardive Dyskinesia with Combined NAD and Glutathione Infusions: Case Report

Abstract

Background

Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder most commonly associated with prolonged exposure to dopamine receptor antagonists. Although vesicular monoamine transporter 2 (VMAT-2) inhibitors such as valbenazine and deutetrabenazine are first-line pharmacologic options, a subset of patients exhibits inadequate response, necessitating alternative therapeutic approaches.

Case presentation

We describe a 21-year-old male with bipolar II disorder who developed progressive perioral and lower limb dyskinesia after four years of risperidone and lithium therapy. Symptoms worsened following abrupt risperidone discontinuation and showed no improvement with valbenazine. He was switched to deutetrabenazine XR 48 mg daily and treated with baclofen, trihexyphenidyl, and weekly infusions of nicotinamide adenine dinucleotide (NAD) and glutathione. While mild lower limb dyskinesia persisted, marked improvement in perioral dyskinetic movements and swallowing allowed him to resume an unrestricted diet.

Conclusion

To the best of our knowledge, this is the first reported case of refractory tardive dyskinesia showing marked improvement with combined NAD and glutathione infusions alongside adjunctive pharmacologic agents. These findings suggest a potential therapeutic role for redox-targeted interventions in treatment-resistant TD and warrant further investigation.

Keywords: Tardive dyskinesia, Treatment-resistant tardive dyskinesia, Nicotinamide adenine dinucleotide, NAD⁺, Glutathione, Oxidative response

Introduction

Tardive dyskinesia (TD) is a hyperkinetic movement disorder characterized by involuntary, repetitive, and polymorphic movements, most frequently involving the perioral region, neck, trunk, and extremities [1]. TD is predominantly associated with chronic exposure to dopamine receptor antagonists, such as antipsychotics, certain antiemetics, antidepressants, and calcium channel blockers. The reported prevalence among patients receiving antipsychotic therapy ranges from 21% to 30%, with substantially higher rates documented in geriatric populations [2]. Although second-generation antipsychotics generally confer a reduced risk relative to first-generation agents, the risk remains clinically relevant. Notably, the overall population at risk

may be increasing due to the broadening therapeutic indications and frequent off-label prescribing of antipsychotics [3].

The onset of TD is typically insidious, and the condition often remains irreversible even after discontinuation of the offending drug. TD imposes a substantial economic burden, diminishes quality of life, and increases mortality rates [4]. Therefore, appropriate prevention and timely intervention are essential. In cases where involuntary movements persist following withdrawal of the causative agent, the subsequent step involves the introduction of pharmacologic agents aimed at mitigating dopaminergic overactivity.

The most widely used therapeutic approach is the administration of vesicular monoamine transporter 2 (VMAT-2) inhibitors, such as valbenazine and deutetrabenazine. VMAT-2 is a critical presynaptic transporter responsible for the storage and release of monoamines, including dopamine, serotonin, and norepinephrine. By inhibiting VMAT-2, these agents attenuate dopamine signaling dysregulation, thereby alleviating excessive D2 receptor blockade [6]. However, due to the inherently irreversible nature of TD, alternative therapeutic strategies have been actively explored. There are some papers on next-step strategies, including baclofen, anticholinergic agents, benzodiazepines, and botulinum toxin injections. Some cases are reported using electroconvulsive therapy (ECT) and deep brain stimulation (DBS) for managing treatment-resistant TD [7,8].

We report a patient who exhibited a suboptimal response to initial treatment with a VMAT-2 inhibitor, necessitating consideration of alternative therapeutic strategies. The patient subsequently received nicotinamide adenine dinucleotide (NAD) and glutathione infusions in combination with other adjunctive pharmacologic agents, resulting in substantial clinical improvement. This case may contribute to expanding the therapeutic options available for the management of treatment-resistant tardive dyskinesia.

Case presentation

A 21-year-old male presented with involuntary movements involving the jaw, perioral region, and legs. He had been receiving risperidone 2 mg and lithium 900 mg daily for five years following a diagnosis of bipolar II disorder at the age of 16.

Four years after initiating treatment, he developed progressive perioral dyskinesia, initially described as protrusion of the mouth, which worsened to cause difficulty in eating, breathing, and articulation. These symptoms precluded the intake of solid food, necessitating a liquid-only diet. He subsequently noted heaviness of the left foot, resulting in a dragging gait. Following the abrupt discontinuation of risperidone, his tongue movements worsened. Valbenazine 60 mg daily was initiated, and risperidone was reintroduced at 1 mg daily with a gradual tapering plan, but no symptomatic improvement was observed.

Upon presentation to another clinic, his Abnormal Involuntary Movement Scale (AIMS) score was 15. Valbenazine 60 mg daily was prescribed with a planned increase to 80 mg after one week, but no clinical benefit was noted. The regimen was subsequently switched to deutetrabenazine XR 48 mg daily, with the addition of trihexyphenidyl 2 mg twice daily and baclofen 20 mg twice daily, along with weekly infusions of nicotinamide adenine dinucleotide

(NAD) 500 mL and glutathione 50ml. Concurrent medications included lithium 900 mg daily and a clonidine 0.1 mg transdermal patch applied weekly. This combination resulted in substantial improvement in tongue movements, although mild dysarthria and intermittent involuntary tongue protrusion persisted.

He was later referred to a neurologist for evaluation and pharmacologic therapy. His AIMS score improved to 6. The current regimen consists of deutetrabenazine XR 48 mg daily, baclofen 20 mg twice daily, diazepam 2 mg twice daily, trihexyphenidyl 2 mg twice daily, clonidine 0.1 mg patch weekly, lithium 450 mg daily, quetiapine 100 mg daily, and weekly NAD, glutathione infusions. Although mild lower limb dyskinesia persists, marked improvement in perioral movements and swallowing has enabled the patient to resume an unrestricted diet.

Discussion

The general concepts on the pathophysiology of TD involve dopamine receptor hypersensitivity, damage to GABAergic and cholinergic neurons, and oxidative stress. Increasing attention has been directed toward oxidative mechanisms in neuronal injury, partly due to evidence supporting the potential therapeutic benefit of vitamin E in TD. In normal cellular circumstances, oxidative reactions are crucial in energy generation and neural protection. Nitric oxide (NO) plays a key role in the redox system, and excessive production of NO may exert neurotoxic effects, leading to structural and functional impairment of neurons [9]. Elevated NO levels facilitate the formation of reactive nitrogen species (RNS), including peroxynitrite and nitrogen dioxide radicals, which induce oxidative stress and inflammatory injury within the central nervous system (CNS). The oxidative stress hypothesis of TD is not mutually exclusive with the dopamine hypothesis. It is suggested that upregulation of dopamine synthesis leads to increased activity of MAO, which leads to the generation of free radicals like hydrogen peroxide and autooxidation of dopamine and thus formation of free radicals and quinines [20].

NO is synthesized by neuronal nitric oxide synthase (NOS1) and endothelial nitric oxide synthase (NOS3), and genetic polymorphisms in NOS3 have been implicated in increased susceptibility to TD [10]. Several other genes involved in oxidative stress defense have also been implicated in TD, with the most consistent association observed for the manganese superoxide dismutase (MnSOD) gene. Additional antioxidant-related genes studied in this context include glutathione S-transferases, NAD(P)H quinone oxidoreductase 1 (NQO1), glutathione peroxidase 1 (GPX1), and nitric oxide synthases (NOS1, NOS3) [11]. Furthermore, redox stress in TD has been demonstrated in studies reporting decreased levels of antioxidant enzymes, such as GPX1 and catalase (CAT1), along with elevated levels of oxidative damage markers, including malondialdehyde and thiobarbituric acid [12,13].

Glutathione, a tripeptide composed of glutamic acid, glycine, and cysteine, plays a central role in cellular antioxidant defense. Under oxidative conditions, glutathione exerts protective effects by undergoing conversion to its oxidized dimeric form. This process is catalyzed by glutathione peroxidase, which reduces hydrogen peroxide using glutathione as a substrate [14]. In pathological mechanisms underlying TD, characterized by oxidative stress and genetic polymorphisms affecting antioxidant pathways, glutathione may represent a potential therapeutic target. Preclinical studies in hyperkinetic disorders, such as Huntington's disease, have shown that dysregulated glutathione metabolism within the indirect pathway leads to excessive

dopaminergic activity in the striatum. Given the shared features of striatal dysfunction and oxidative stress between Huntington's disease and TD, glutathione supplementation could be of therapeutic relevance [15,16]. This is further supported by clinical evidence indicating that other antioxidants, such as vitamin E, confer modest benefits in TD [17].

NAD is a critical redox coenzyme that interconverts between its oxidized (NAD⁺) and reduced (NADH) forms. The NAD⁺/NADH ratio plays a pivotal role in regulating energy production, metabolic homeostasis, mitochondrial function, and DNA repair, necessitating tight regulation of its synthesis and utilization to preserve cellular integrity [18]. Studies measuring CSF levels of substrates of mitochondrial energy metabolism have found that aspartate levels are significantly elevated in patients with tardive dyskinesia and correlate with the total AIMS score. This finding, consistent with inhibition of complex I of the electron transport chain in the mitochondria, could be associated with increased free radical formation. [19].

This is consistent with findings that antipsychotics, including the second generation, target the mitochondria, alter oxidative phosphorylation & mRNA expression, and lead to significantly decreased ATP production & increased oxidative stress [21]. Supplementation of NAD in neurodegenerative diseases has been shown to reduce free radical stress, and reduce the accumulation of damaged mitochondria [22]. Given the above, NAD must be strongly considered as a potential pharmacotherapy for treatment-resistant Tardive Dyskinesia. This case report is the first to demonstrate the therapeutic utility of this drug to manage this condition.

To the best of our knowledge, this case report represents the first documented instance of treating refractory tardive dyskinesia with combined NAD and glutathione infusions alongside adjunctive pharmacologic agents, potentially contributing to the expansion of therapeutic strategies for managing treatment-resistant cases.

Conclusion

TD remains a challenging condition to manage, particularly in patients who exhibit inadequate responses to standard therapies such as VMAT-2 inhibitors. Oxidative stress is increasingly recognized as a key contributor to its pathophysiology, highlighting the therapeutic potential of antioxidant-based interventions. In this report, we describe, to the best of our knowledge, the first documented case of refractory TD successfully managed with combined NAD and glutathione infusions in conjunction with adjunctive pharmacologic agents. The marked clinical improvement observed in this patient supports further exploration of redox-targeted therapies in treatment-resistant TD. Future studies are warranted to validate these findings and to clarify the underlying mechanisms of benefit.

Declarations

Acknowledgement:

The authors would like to thank their colleagues for their support and guidance in the preparation of this case report.

Source of Funding:

None

Conflict of Interest:

None

Reference

1. Caroff S. N. (2020). Recent Advances in the Pharmacology of Tardive Dyskinesia. *Clinical psychopharmacology and neuroscience: the official scientific Journal of the Korean College of Neuropsychopharmacology*, 18(4), 493–506. <https://doi.org/10.9758/cpn.2020.18.4.493>
2. Carbon, M., Hsieh, C. H., Kane, J. M., & Correll, C. U. (2017). Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. *The Journal of Clinical Psychiatry*, 78(3), e264–e278. <https://doi.org/10.4088/JCP.16r10832>
3. Factor, S. A., Burkhard, P. R., Caroff, S., Friedman, J. H., Marras, C., Tinazzi, M., & Comella, C. L. (2019). Recent developments in drug-induced movement disorders: a mixed picture. *The Lancet. Neurology*, 18(9), 880–890. [https://doi.org/10.1016/S1474-4422\(19\)30152-8](https://doi.org/10.1016/S1474-4422(19)30152-8)
4. Dean, C. E., & Thuras, P. D. (2009). Mortality and tardive dyskinesia: long-term study using the US National Death Index. *The British Journal of psychiatry: the Journal of mental science*, 194(4), 360–364. <https://doi.org/10.1192/bjp.bp.108.049395>
5. Baminiwatta, A., & Correll, C. U. (2023). Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications. *Frontiers in psychiatry*, 14, 1194222. <https://doi.org/10.3389/fpsy.2023.1194222>

6. Li, C., Zhuo, C., Ma, X., Li, R., Chen, X., Li, Y., Zhang, Q., Yang, L., Tian, H., & Wang, L. (2025). Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia. *Schizophrenia (Heidelberg, Germany)*, 11(1), 69. <https://doi.org/10.1038/s41537-025-00618-w>

7. Irinaka, K., Itoh, Y., Yoshizawa, K., Ogasawara, M., Ayabe, N., Mishima, K., & Takeshima, M. (2024). Successful Electroconvulsive Therapy for Tardive Dyskinesia and Tardive Dystonia Refractory to Valbenazine Treatment: A Case Report and Narrative Literature Review. *Clinical psychopharmacology and neuroscience: the official scientific Journal of the Korean College of Neuropsychopharmacology*, 22(4), 688–696. <https://doi.org/10.9758/cpn.24.1185>

8. Krause, P., Kroneberg, D., Gruber, D., Koch, K., Schneider, G. H., & Kühn, A. A. (2022). Long-term effects of pallidal deep brain stimulation in tardive dystonia: a follow-up of 5-14 years. *Journal of Neurology*, 269(7), 3563–3568. <https://doi.org/10.1007/s00415-022-10965-8>

9. Li, C., Zhuo, C., Ma, X., Li, R., Chen, X., Li, Y., Zhang, Q., Yang, L., Tian, H., & Wang, L. (2025). Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia. *Schizophrenia (Heidelberg, Germany)*, 11(1), 69. <https://doi.org/10.1038/s41537-025-00618-w>

10. Liou, Y. J., Lai, I. C., Lin, M. W., Bai, Y. M., Lin, C. C., Liao, D. L., Chen, J. Y., Lin, C. Y., & Wang, Y. C. (2006). Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. *Pharmacogenetics and genomics*, 16(3), 151–157. <https://doi.org/10.1097/01.fpc.0000184958.05775.66>

11. Cho, C. H., & Lee, H. J. (2013). Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. *Progress in neuro-psychopharmacology & biological psychiatry*, 46, 207–213. <https://doi.org/10.1016/j.pnpbp.2012.10.018>

12. Waln, O., & Jankovic, J. (2013). An update on tardive dyskinesia: from phenomenology to treatment. *Tremor and other hyperkinetic movements (New York, N.Y.)*, 3, tre-03-161-4138-1. <https://doi.org/10.7916/D88P5Z71>

13. Wu, Q., Yuan, F., Zhang, S., Liu, W., Miao, Q., Zheng, X., Lu, S., & Hou, K. (2022). Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients. *Disease markers*, 2022, 1767989. <https://doi.org/10.1155/2022/1767989>

218

219 14. Poladian, N., Navasardyan, I., Narinyan, W., Orujyan, D., & Venketaraman, V. (2023).
220 Potential Role of Glutathione Antioxidant Pathways in the Pathophysiology and Adjunct
221 Treatment of Psychiatric Disorders. *Clinics and practice*, 13(4), 768–779.
222 <https://doi.org/10.3390/clinpract13040070>

223

224 15. Malik, M. Y., Guo, F., Asif-Malik, A., Eftychidis, V., Barkas, N., Eliseeva, E., Timm, K. N.,
225 Wolska, A., Bergin, D., Zonta, B., Ratz-Wirsching, V., von Hörsten, S., Walton, M. E., Magill,
226 P. J., Nerlov, C., & Minichiello, L. (2024). Impaired striatal glutathione-ascorbate metabolism
227 induces transient dopamine increase and motor dysfunction. *Nature Metabolism*, 6(11), 2100–
228 2117. <https://doi.org/10.1038/s42255-024-01155-z>

229

230 16. Stahl S. M. (2017). Neuronal traffic signals in tardive dyskinesia: not enough "stop" in the
231 motor striatum. *CNS spectrums*, 22(6), 427–434. <https://doi.org/10.1017/S109285291700061X>

232

233 17. Soares, K. V., & McGrath, J. J. (1999). The treatment of tardive dyskinesia--a systematic
234 review and meta-analysis. *Schizophrenia research*, 39(1), 1–18. [https://doi.org/10.1016/s0920-](https://doi.org/10.1016/s0920-9964(99)00021-3)
235 [9964\(99\)00021-3](https://doi.org/10.1016/s0920-9964(99)00021-3)

236

237 18. Yusri, K., Jose, S., Vermeulen, K. S., Tan, T. C. M., & Sorrentino, V. (2025). The role of
238 NAD⁺ metabolism and its modulation of mitochondria in aging and disease. *npj metabolic*
239 *health and disease*, 3(1), 26. <https://doi.org/10.1038/s44324-025-00067-0>

240

241 19. Goff, D. C., Tsai, G., Beal, M. F., & Coyle, J. T. (1995). Tardive dyskinesia and substrates of
242 energy metabolism in CSF. *The American Journal of Psychiatry*, 152(12), 1730–1736.
243 <https://doi.org/10.1176/ajp.152.12.1730>

244

245 20. Elkashef, A. M., & Wyatt, R. J. (1999). Tardive dyskinesia: possible involvement of free
246 radicals and treatment with vitamin E. *Schizophrenia bulletin*, 25(4), 731–740.
247 <https://doi.org/10.1093/oxfordjournals.schbul.a033414>

248

249 21. Scaini, G., Quevedo, J., Velligan, D., Roberts, D. L., Raventos, H., & Walss-Bass, C. (2018).
250 Second-generation antipsychotic-induced mitochondrial alterations: Implications for increased

251 risk of metabolic syndrome in patients with schizophrenia. *European neuropsychopharmacology:*
252 *the Journal of the European College of Neuropsychopharmacology*, 28(3), 369–380.
253 <https://doi.org/10.1016/j.euroneuro.2018.01.004>

254
255 22. Wang, H., Du, Y., Guan, J., Wang, X., & Fu, J. (2021). NAD⁺ improves cognitive function
256 and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS
257 production in chronic cerebral hypoperfusion models through the Sirt1/PGC-1 α pathway. *Journal*
258 *of Neuroinflammation*, 18(1), 207. <https://doi.org/10.1186/s12974-021-02250-8>

259
260
261
UNDER PEER REVIEW IN IJAR